Caroline A Presley1, Jonathan Chipman2, Jea Young Min3,4, Carlos G Grijalva3,4, Robert A Greevy2, Marie R Griffin3,4,5, Christianne L Roumie3,5. 1. Department of Medicine, University of Alabama at Birmingham, Nashville, Tennessee. 2. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee. 3. Veterans Health Administration-Tennessee Valley Healthcare System, Geriatric Research Education and Clinical Center (GRECC), Nashville. 4. Department of Health Policy. 5. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Abstract
BACKGROUND: It is unknown whether observational studies evaluating the association between antidiabetic medications and mortality adequately account for frailty. Our objectives were to evaluate if frailty was a potential confounder in the relationship between antidiabetic medication regimen and mortality and how well administrative and clinical electronic health record (EHR) data account for frailty. METHODS: We conducted a retrospective cohort study in a single Veterans Health Administration (VHA) healthcare system of 500 hospitalizations-the majority due to heart failure-of Veterans who received regular VHA care and initiated type 2 diabetes treatment from 2001 to 2008. We measured frailty using a modified frailty index (FI, >0.21 frail). We obtained antidiabetic medication regimen and time-to-death from administrative sources. We compared FI among patients on different antidiabetic regimens. Stepwise Cox proportional hazards regression estimated time-to-death by demographic, administrative, clinical EHR, and FI data. RESULTS: Median FI was 0.22 (interquartile range 0.18, 0.27). Frailty differed across antidiabetic regimens (p < .001). An FI increase of 0.05 was associated with an increased risk of death (hazard ratio 1.45, 95% confidence interval 1.32, 1.60). Cox proportional hazards model for time-to-death including demographic, administrative, and clinical EHR data had a c-statistic of 0.70; adding FI showed marginal improvement (c-statistic 0.72). CONCLUSIONS: Frailty was associated with antidiabetic regimen and death, and may confound that relationship. Demographic, administrative, and clinical EHR data, commonly used to balance differences among exposure groups, performed moderately well in assessing risk of death, with minimal gain from adding frailty. Study design and analytic techniques can help minimize potential confounding by frailty in observational studies. Published by Oxford University Press on behalf of The Gerontological Society of America 2018.
BACKGROUND: It is unknown whether observational studies evaluating the association between antidiabetic medications and mortality adequately account for frailty. Our objectives were to evaluate if frailty was a potential confounder in the relationship between antidiabetic medication regimen and mortality and how well administrative and clinical electronic health record (EHR) data account for frailty. METHODS: We conducted a retrospective cohort study in a single Veterans Health Administration (VHA) healthcare system of 500 hospitalizations-the majority due to heart failure-of Veterans who received regular VHA care and initiated type 2 diabetes treatment from 2001 to 2008. We measured frailty using a modified frailty index (FI, >0.21 frail). We obtained antidiabetic medication regimen and time-to-death from administrative sources. We compared FI among patients on different antidiabetic regimens. Stepwise Cox proportional hazards regression estimated time-to-death by demographic, administrative, clinical EHR, and FI data. RESULTS: Median FI was 0.22 (interquartile range 0.18, 0.27). Frailty differed across antidiabetic regimens (p < .001). An FI increase of 0.05 was associated with an increased risk of death (hazard ratio 1.45, 95% confidence interval 1.32, 1.60). Cox proportional hazards model for time-to-death including demographic, administrative, and clinical EHR data had a c-statistic of 0.70; adding FI showed marginal improvement (c-statistic 0.72). CONCLUSIONS: Frailty was associated with antidiabetic regimen and death, and may confound that relationship. Demographic, administrative, and clinical EHR data, commonly used to balance differences among exposure groups, performed moderately well in assessing risk of death, with minimal gain from adding frailty. Study design and analytic techniques can help minimize potential confounding by frailty in observational studies. Published by Oxford University Press on behalf of The Gerontological Society of America 2018.
Authors: Sebastian Schneeweiss; Amanda R Patrick; Til Stürmer; M Alan Brookhart; Jerry Avorn; Malcolm Maclure; Kenneth J Rothman; Robert J Glynn Journal: Med Care Date: 2007-10 Impact factor: 2.983
Authors: Carmen C Cuthbertson; Anna Kucharska-Newton; Keturah R Faurot; Til Stürmer; Michele Jonsson Funk; Priya Palta; B Gwen Windham; Sydney Thai; Jennifer L Lund Journal: Epidemiology Date: 2018-07 Impact factor: 4.822
Authors: Keturah R Faurot; Michele Jonsson Funk; Virginia Pate; M Alan Brookhart; Amanda Patrick; Laura C Hanson; Wendy Camelo Castillo; Til Stürmer Journal: Pharmacoepidemiol Drug Saf Date: 2014-10-21 Impact factor: 2.890
Authors: Jodi B Segal; Hsien-Yen Chang; Yu Du; Jeremy D Walston; Michelle C Carlson; Ravi Varadhan Journal: Med Care Date: 2017-07 Impact factor: 2.983
Authors: Christianne L Roumie; Adriana M Hung; Robert A Greevy; Carlos G Grijalva; Xulei Liu; Harvey J Murff; Tom A Elasy; Marie R Griffin Journal: Ann Intern Med Date: 2012-11-06 Impact factor: 25.391
Authors: Christianne L Roumie; Robert A Greevy; Carlos G Grijalva; Adriana M Hung; Xulei Liu; Harvey J Murff; Tom A Elasy; Marie R Griffin Journal: JAMA Date: 2014-06-11 Impact factor: 56.272
Authors: Gloria A Aguayo; Anne-Françoise Donneau; Michel T Vaillant; Anna Schritz; Oscar H Franco; Saverio Stranges; Laurent Malisoux; Michèle Guillaume; Daniel R Witte Journal: Am J Epidemiol Date: 2017-08-15 Impact factor: 4.897
Authors: Caroline A Presley; Jea Young Min; Jonathan Chipman; Robert A Greevy; Carlos G Grijalva; Marie R Griffin; Christianne L Roumie Journal: BMJ Open Date: 2018-03-25 Impact factor: 2.692
Authors: Rasheeda K Hall; Sarah Morton; Jonathan Wilson; Dae Hyun Kim; Cathleen Colón-Emeric; Julia J Scialla; Alyssa Platt; Patti L Ephraim; L Ebony Boulware; Jane Pendergast Journal: Kidney360 Date: 2022-07-19
Authors: Jea Young Min; Amber J Hackstadt; Marie R Griffin; Robert A Greevy; Jonathan Chipman; Carlos G Grijalva; Adriana M Hung; Christianne L Roumie Journal: Diabetes Obes Metab Date: 2019-08-29 Impact factor: 6.577